A 48-year-old woman presents with a 2 cm invasive ductal carcinoma of the left breast, ER/PR positive, HER2 negative, with no axillary lymph node involvement (Stage IIA). She undergoes breast-conserving surgery with sentinel lymph node biopsy. What is the drug of choice for adjuvant systemic therapy?

Explanation

## Adjuvant Therapy for Hormone-Receptor-Positive, HER2-Negative Breast Cancer **Key Point:** For ER/PR-positive, HER2-negative early breast cancer, endocrine therapy (tamoxifen or aromatase inhibitors) is the cornerstone of adjuvant treatment. Chemotherapy is considered based on tumor size, grade, and nodal status using tools like Oncotype DX or Magee algorithm. ### Hormone Receptor Status and Treatment Selection | Feature | Tamoxifen | Aromatase Inhibitors (AI) | Trastuzumab | Paclitaxel | |---------|-----------|--------------------------|-------------|------------| | **Indication** | ER/PR+ (any menopausal status) | ER/PR+, postmenopausal preferred | HER2+ breast cancer | Triple-negative or HER2+ with chemotherapy | | **Mechanism** | Selective estrogen receptor modulator | Blocks aromatase enzyme | Anti-HER2 monoclonal antibody | Microtubule stabilizer (chemotherapy) | | **Duration** | 5–10 years | 5–10 years | 1 year (with chemotherapy) | 4–6 cycles (chemotherapy) | | **Menopausal Status** | All | Postmenopausal or with ovarian suppression | All | All | **High-Yield:** In this case: - Tumor is **ER/PR positive** → endocrine therapy is indicated - Tumor is **HER2 negative** → trastuzumab is NOT indicated - Tumor is **2 cm, Stage IIA, node-negative** → chemotherapy may be considered, but endocrine therapy is mandatory - **Tamoxifen** is the first-line choice for premenopausal women or when AI is contraindicated; **AIs** are preferred in postmenopausal women **Clinical Pearl:** The question does not specify menopausal status. In Indian practice and NEET PG exams, when menopausal status is not explicitly stated and the tumor is ER/PR+, **tamoxifen** is the safest first-line answer because it is effective in both premenopausal and postmenopausal women. AIs are preferred in postmenopausal women but require either ovarian suppression or confirmed postmenopausal status in premenopausal women. **Mnemonic:** **CHAT** — Chemotherapy (if high-risk), Hormonal therapy (ER/PR+), Anti-HER2 (HER2+), Targeted therapy (genomic signature) ### Why Tamoxifen is Correct Tamoxifen is a selective estrogen receptor modulator (SERM) that: 1. Blocks estrogen binding to ER in breast tissue 2. Is effective in both premenopausal and postmenopausal women 3. Reduces recurrence and improves overall survival in ER/PR+ breast cancer 4. Has a well-established safety profile in the Indian population 5. Is the standard of care when menopausal status is not specified